Granahan Investment Management, L recently announced the acquisition of new stake in Biomerica Inc. (NASDAQ:BMRA). The institutional investor has increased its shareholding in the Healthcare company by 1.57% to 1.16 million shares with purchase of 17996.0 shares. This fresh investment now brings its stake to 6.91% valued currently at $1.08 million.
Currently, there are 16.82M common shares owned by the public and among those 15.59M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 13 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 13 of these insider trades were purchases, accounting for 23,128 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Biomerica Inc. are JNL Multi-Manager Small Cap Growt, Wasatch Micro Cap Value Fund, and Vanguard Total Stock Market ETF. JNL Multi-Manager Small Cap Growt owns 0.61 million shares of the company’s stock, all valued at over $0.57 million. The company sold 39000.0 shares recently to bring their total holdings to about 3.63% of the shares outstanding. Vanguard Total Stock Market ETF now owns shares totaling to 2.37% of the shares outstanding.
However, the script later moved the day high at 2.1300, up 66.67%. The company’s stock has a 5-day price change of 44.74% and 48.65% over the past three months. BMRA shares are trading -50.75% year to date (YTD), with the 12-month market performance down to -53.12% lower. It has a 12-month low price of $0.70 and touched a high of $3.80 over the same period. BMRA has an average intraday trading volume of 54.50K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 71.65%, 84.68%, and 25.58% respectively.
Institutional ownership of Biomerica Inc. (NASDAQ: BMRA) shares accounts for 24.13% of the company’s 16.82M shares outstanding. Mutual fund holders own 12.50%, while other institutional holders and individual stakeholders account for 16.51% and 11.63% respectively.
It has a market capitalization of $27.75M and a beta (3y monthly) value of -0.93. The earnings-per-share (ttm) stands at -$0.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 21.79% over the week and 10.30% over the month.
Analysts forecast that Biomerica Inc. (BMRA) will achieve an EPS of $Biomea Fusion, Inc. for the current quarter, $13.99 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $BioMarin Pharmaceutical Inc. while analysts give the company a high EPS estimate of $Banco Macro S.A.. Comparatively, EPS for the current quarter was $Neumora Therapeutics, Inc. a year ago.
Looking at the support for the BMRA, a number of firms have released research notes about the stock. Colliers Securities stated their Buy rating for the stock in a research note on November 10, 2020, with the firm’s price target at $13.
